Evercore ISI: Raised Nvidia(NASDAQ:NVDA) price target to $300 Maintain outperform rating

/ / Technology / ,

Evercore ISI analyst C.J. Muse raised its price target on Nvidia(NASDAQ:NVDA)  to $300 from $245, maintaining the stock’s outperform rating after the company reported better-than-expected results for the January quarter and better guidance for the April quarter. With data center revenue expected to accelerate throughout 2023, the analyst said the earnings report “should be welcomed” given pre-report concerns about slowing data center demand and the likelihood of falling total revenue guidance for the April quarter.

Evercore ISI: Raised Nvidia(NASDAQ:NVDA) price target to $300 Maintain outperform rating Read Post »

Goldman Sachs raised NVIDIA (NASDAQ:NVDA) target price to $275 from $226

/ / Technology / ,

Goldman Sachs reported that NVIDIA’s (NASDAQ:NVDA) fiscal fourth quarter results were impressive, with non-GAAP ex-board (SBC) earnings of $0.88 per share, 9% higher than market expectations, mainly due to increased gaming revenue and strict expense management. Goldman Sachs upgraded the rating of Nvidia from neutral to buy, and raised its target price to $275 from $226, reflecting a renewed acceleration in growth.

Goldman Sachs raised NVIDIA (NASDAQ:NVDA) target price to $275 from $226 Read Post »

Morgan Stanley lowered Moderna (NASDAQ:MRNA) price target to $185 from $205

/ / Health Care / ,

Morgan Stanley said in a research note that it lowered its Moderna (NASDAQ:MRNA) price target from $205 to $185 due to increased fees and capital expenditures, while maintaining a “hold” rating. The bank noted that Moderna’s fourth-quarter results were generally in line with expectations. The higher-than-expected guidance of 35%-40% for the cost of main business in 2023 is the most concerned downside factor in the bank’s forecast. Morgan Stanley added that advance filings for personalized cancer vaccines (PCV), flu 2024 and respiratory syncytial virus (RSV) vaccines, as well as a stronger U.S. commercial coronavirus market, are potential short-term upside drivers.

Morgan Stanley lowered Moderna (NASDAQ:MRNA) price target to $185 from $205 Read Post »

Moderna(NASDAQ:MRNA) Q4 2022 revenues of $5.084 billion,down 29.4% year-over-year

/ / Health Care /

February 23, 2023— Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today reported financial results and provided business updates for the fourth quarter and fiscal year 2022. Moderna(NASDAQ:MRNA)  reported Q4 earnings of $3.61 per diluted share, Analysts polled by Capital IQ expected $4.75. Moderna(NASDAQ:MRNA)  Revenue for the quarter ended Dec. 31 was $4.86 billion, Analysts surveyed by Capital IQ expected $5.02 billion. Fourth quarter 2022 revenues of $5.1 billion; GAAP net income of $1.5 billion and GAAP diluted EPS of $3.61。 Full-year 2022 revenues of $19.3 billion; GAAP net income of $8.4 billion and GAAP diluted EPS of $20.12。 Cash used for repurchases of common stock was $3.3 billion for the full year 2022. Business outlook: The Company expects product sales in the first half of 2023 of approximately $2.0 billion. Research & Development (R&D) and Selling, General & Administrative (SG&A) Expenses: Full-year expenses

Moderna(NASDAQ:MRNA) Q4 2022 revenues of $5.084 billion,down 29.4% year-over-year Read Post »

Scroll to Top